Abeona Stock Today

ABEO
 Stock
  

USD 3.07  0.07  2.33%   

Market Performance
0 of 100
Odds Of Distress
Less than 1
Abeona Therapeutics is selling for 3.07 as of the 28th of September 2022. This is a 2.33 percent up since the beginning of the trading day. The stock's open price was 3.0. Abeona Therapeutics has a very small chance of experiencing financial distress in the next few years, but has generated negative returns over the last 90 days. Equity ratings for Abeona Therapeutics are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 8th of October 2020 and ending today, the 28th of September 2022. Click here to learn more.
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Abeona Therapeutics Inc. was incorporated in 1974 and is headquartered in New York, New York. Abeona Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 146.62 M outstanding shares of which 213.12 K shares are presently shorted by private and institutional investors with about 1.18 trading days to cover. More on Abeona Therapeutics

Moving together with Abeona Therapeutics

+0.87DISWalt Disney Fiscal Year End 9th of November 2022 PairCorr
+0.69JPMJP Morgan Chase Fiscal Year End 13th of January 2023 PairCorr

Moving against Abeona Therapeutics

-0.63HPQHp Inc Fiscal Year End 22nd of November 2022 PairCorr
Follow Valuation Odds of Bankruptcy
Check how we calculate scores

Abeona Therapeutics Stock Highlights

Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Abeona Therapeutics' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Abeona Therapeutics or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
Abeona Therapeutics generated a negative expected return over the last 90 days
Abeona Therapeutics has high historical volatility and very poor performance
Abeona Therapeutics is unlikely to experience financial distress in the next 2 years
The company reported the previous year's revenue of 3.35 M. Net Loss for the year was (89.72 M) with loss before overhead, payroll, taxes, and interest of (299 K).
Abeona Therapeutics currently holds about 31.32 M in cash with (65.77 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.33, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Latest headline from MacroaxisInsider: Payment of 479 shares by Omalley Brendan M of Abeona Therapeutics subject to Rule 16b-3
CEO and President and DirectorTimothy Miller
Average Analyst Recommendation
Analysts covering Abeona Therapeutics report their recommendations after researching Abeona Therapeutics' financial statements, talking to executives and customers, or listening in on Abeona Therapeutics' conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Abeona Therapeutics. The Abeona consensus assessment is calculated by taking the average forecast from all of the analysts covering Abeona Therapeutics.
Macroaxis Advice
Unlike general analyst consensus, Macroaxis buy hold or sell recommendation is provided in the context of your current investment horizon and risk tolerance. The advice algorithm takes into account all of Abeona Therapeutics' available fundamental, technical, and predictive indicators. Your current horizon is 90 days - details
Abeona Therapeutics (ABEO) is traded on NASDAQ Exchange in USA and employs 90 people. The company currently falls under 'Small-Cap' category with current market capitalization of 439.85 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Abeona Therapeutics's market, we take the total number of its shares issued and multiply it by Abeona Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities. Abeona Therapeutics conducts business under Healthcare sector and is part of Biotechnology industry. The entity has 146.62 M outstanding shares of which 213.12 K shares are presently shorted by private and institutional investors with about 1.18 trading days to cover. Abeona Therapeutics currently holds about 31.32 M in cash with (65.77 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.33, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Abeona Therapeutics Probability Of Bankruptcy
Ownership
Abeona Therapeutics retains a total of 146.62 Million outstanding shares. Abeona Therapeutics shows 10.27 percent if its outstanding shares held by insiders and 10.27 percent owned by other corporate entities . Remember, it does not matter who owns the company or if the company is currently losing money. If the true value of the company is more than the market pays for it currently, you can still have a good investment opportunity.

Ownership Allocation (%)

Check Abeona Ownership Details

Abeona Stock Price Odds Analysis

Proceeding from a normal probability distribution, the odds of Abeona Therapeutics jumping above the current price in 90 days from now is about 82.44%. The Abeona Therapeutics probability density function shows the probability of Abeona Therapeutics stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days the stock has a beta coefficient of 1.3947. This suggests as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Abeona Therapeutics will likely underperform. Additionally, the company has a negative alpha, implying that the risk taken by holding this instrument is not justified. Abeona Therapeutics is significantly underperforming DOW.
  Odds Below 3.07HorizonTargetOdds Above 3.07
17.53%90 days
 3.07 
82.44%
Based on a normal probability distribution, the odds of Abeona Therapeutics to move above the current price in 90 days from now is about 82.44 (This Abeona Therapeutics probability density function shows the probability of Abeona Stock to fall within a particular range of prices over 90 days) .

Abeona Stock Institutional Holders

Institutional Holdings refers to the ownership stake in Abeona Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Abeona Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Abeona Therapeutics' value.
InstituionSecurity TypeTotal SharesValue
Adage Capital Partners Gp LlcCommon SharesM1.7 M
Renaissance Technologies LlcCommon Shares2.4 M499 K
View Abeona Therapeutics Diagnostics

Abeona Therapeutics Risk Profiles

Investors will always prefer to have the highest possible return on investment while minimizing volatility. Abeona Therapeutics market risk premium is the additional return an investor will receive from holding Abeona Therapeutics long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Abeona Therapeutics. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Although Abeona Therapeutics' alpha and beta are two of the key measurements used to evaluate Abeona Therapeutics' performance over the market, the standard measures of volatility play an important role as well.

Abeona Stock Against Markets

Picking the right benchmark for Abeona Therapeutics stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Abeona Therapeutics stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Abeona Therapeutics is critical whether you are bullish or bearish towards Abeona Therapeutics at a given time.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Abeona Therapeutics without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Transaction History Now

   

Transaction History

View history of all your transactions and understand their impact on performance
All  Next Launch Module

Abeona Therapeutics Corporate Directors

Abeona Therapeutics corporate directors refer to members of an Abeona Therapeutics board of directors. The board of directors generally takes responsibility for the Abeona Therapeutics' affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of Abeona Therapeutics' board members must vote for the resolution. The Abeona Therapeutics board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.
Mark Alvino - Independent DirectorProfile
Mark Ahn - Independent DirectorProfile
Stephen Howell - Independent DirectorProfile
Jeffrey Davis - COO and DirectorProfile

Invested in Abeona Therapeutics?

The danger of trading Abeona Therapeutics is mainly related to its market volatility and company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Abeona Therapeutics is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Abeona Therapeutics. The Shape ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Abeona Therapeutics is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Please continue to Trending Equities. Note that the Abeona Therapeutics information on this page should be used as a complementary analysis to other Abeona Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.

Complementary Tools for Abeona Stock analysis

When running Abeona Therapeutics price analysis, check to measure Abeona Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Abeona Therapeutics is operating at the current time. Most of Abeona Therapeutics' value examination focuses on studying past and present price action to predict the probability of Abeona Therapeutics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Abeona Therapeutics' price. Additionally, you may evaluate how the addition of Abeona Therapeutics to your portfolios can decrease your overall portfolio volatility.
Stock Screener
Find equities using custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Go
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Go
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Go
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Go
ETF Directory
Find actively traded Exchange Traded Funds (ETF) from around the world
Go
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Go
Commodity Channel Index
Use Commodity Channel Index to analyze current equity momentum
Go
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Go
Is Abeona Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Abeona Therapeutics. If investors know Abeona will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Abeona Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Abeona Therapeutics is measured differently than its book value, which is the value of Abeona that is recorded on the company's balance sheet. Investors also form their own opinion of Abeona Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Abeona Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Abeona Therapeutics' market value can be influenced by many factors that don't directly affect Abeona Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Abeona Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine Abeona Therapeutics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Abeona Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.